Eton Pharmaceuticals : Investor Day and Fourth Quarter 2024 Earnings Presentation (ab9253)
ETON
2025 INVESTOR DAY
March 18, 2025
Agenda
Today's Speakers
SEAN BRYNJELSEN
JAMES GRUBER
DAVID KREMPA
IPEK ERDOGAN-TRINKAUS
Chief Executive Officer
Chief Financial Officer
Chief Business Officer
Chief Commercial Officer
Reviewing Eton's Transformational Six Months
Our Vision
To build a leading ultra-raredisease company
with a relentless commitment to patients and innovative therapies.
Patients First
Ultra-Rare Focus
The Greatest Number of
New Therapies Achievable
Clearing the path for
Making the greatest
Rapidly growing our
better patient access and
impact where it matters
portfolio to bring more
therapy experience
the most - and too rare
innovative treatments
for big pharma
to patients
Transformational 6 Months
Expanded portfolio, delivered record revenue, strong commercial launch momentum
Acquired 2 High
Added 3 Attractive
Exceptional
Value Commercial
Pipeline Assets
Execution Across
Products
(Amglidia®,
All Functions
(Increlex®, Galzin®)
ET-700, ET-800)
Acquired
Reported record 3Q
Galzin
product revenue and
Closed
Galzin
commercial
Reported
reached GAAP
launch
Signed
profitability
Acquired
acquisition
Launched
Positive
record Q4
Increlex
of Increlex
new metabolic
product sales
ET-600 clinical
acquisition
Amglidia
sales force
study results
OCT 3
NOV 12
NOV 25
DEC 19
DEC 30
JAN 2
MAR 3
MAR 14
MAR 18
3 Pillar Growth Strategy
Eton was successfully built with a three-pillar strategy and is well positioned to sustain the momentum
Organic Growth of
Existing Products
Track Record
16 straight quarters of sequential revenue growth (driven by Alkindi Sprinkle and Carglumic Acid)
Outlook
Attractive long-term growth opportunities for Increlex, Galzin, and Alkindi Sprinkle
Internal Pipeline
Products
Track Record
Developed ET-400 internally
Outlook
Additional high-value programs in late-stage development (ET-600, ET-700, ET-800, Amglidia®, Zeneo®)
External Acquisitions
And Licensing
Track Record
Executed high-ROI acquisitions of Increlex, Galzin, Carglumic Acid, and Alkindi Sprinkle
Outlook
Well positioned to continue acquiring strategically and financially attractive products. Strong balance sheet with significant access to capital.
Eton's commercial strategy is designed to
effectively meet the distinct needs of ultra-rare patient populations
Concentrated prescriber bases | Small number of specialists within pediatric endocrinology and metabolics enables highly targeted, efficient sales force coverage and marketing efforts
Meaningful partnerships with patient advocacy groups | Through deep collaboration, Eton supports patient and caregiver communities to drive awareness, promote education, and enhance patient resources
Strategic collaboration with key thought leaders and professional societies | Advisory boards and joint initiatives to engage with healthcare professionals and societies leading therapeutic advancements
Eton Cares patient support program for all Rx products | $0 co-payfor eligible patients, quick-startand bridge programs, nurse hotline, monthly patient check-in,and exclusive distribution through high-touchspecialty pharmacy
Built one of the broadest ultra rare disease portfolios in the industry
1
CMC Development
Phase III/Pivotal Study
Increlex® - Severe Primary Insulin-Like Growth Factor
1 Deficiency
2
Alkindi Sprinkle® - Pediatric Adrenal Insufficiency
3
Galzin® - Wilson disease
4
Carglumic Acid - Hyperammonemia
5
PKU GoLike® - Phenylketonuria
6
Betaine Anhydrous - Homocystinuria
7
Nitisinone - Hereditary Tyrosinemia Type 1 (HT-1)
8
ET-400
- Pediatric Adrenal Insufficiency
9
ET-600
- Diabetes Insipidus
10
Amglidia® - Neonatal Diabetes
11
ET-700
- Wilson disease
12
ET-800
- Endocrinology
13 Zeneo® - Adrenal Crisis
PEDIATRIC ENDOCRINOLOGY
METABOLIC
NDA Submission
Commercial
Disclosing for
First Time
ADDED IN THE LAST 6 MONTHS
13
Products
7
Commercial
Products
6
Pipeline
Programs
Disclaimer
Eton Pharmaceuticals Inc. published this content on March 18, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 19, 2025 at 06:04:03.623.